Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02981628
Title Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Children's Oncology Group

childhood B-cell acute lymphoblastic leukemia

B-lymphoblastic leukemia/lymphoma


Inotuzumab ozogamicin

Age Groups: child | adult
Covered Countries USA

No variant requirements are available.